Answers are grounded in this paper and cite their sources.
This analysis highlights visual acuity as a key measure of efficacy in anti-VEGF therapy for neovascular AMD, suggesting improvements are necessary.
Precis: Anti-vascular endothelial growth factor therapy transformed neovascular age-related macular degeneration, but durability and anatomic drying gradually became proxies for efficacy. Visual acuity gains have plateaued across successive agents. Feedback-driven treatment strategies obscure differences. Future progress should be judged by meaningful improvements in visual function, not extended dosing intervals alone.
No takes yet. Share an insight, caveat, or question.
Richard F. Spaide (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: